共 50 条
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
被引:130
|作者:
del Alcazar, Carlos Rodrigo Gil
[1
]
Hardebeck, Molly Catherine
[1
]
Mukherjee, Bipasha
[1
]
Tomimatsu, Nozomi
[1
]
Gao, Xiaohuan
[1
]
Yan, Jingsheng
[2
]
Xie, Xian-Jin
[2
]
Bachoo, Robert
[3
]
Li, Li
[3
,4
]
Habib, Amyn A.
[3
,4
]
Burma, Sandeep
[1
]
机构:
[1] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA
[4] VA North Texas Hlth Care Syst, Dallas, TX USA
基金:
美国国家航空航天局;
关键词:
PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET;
DEPENDENT PROTEIN-KINASE;
RAPAMYCIN INHIBITOR;
PRECLINICAL EVALUATION;
ADJUVANT TEMOZOLOMIDE;
DAMAGE RESPONSE;
CANCER-CELLS;
IN-VIVO;
ATM;
RADIOTHERAPY;
D O I:
10.1158/1078-0432.CCR-13-1607
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Purpose: Inhibitors of the DNA damage response (DDR) have great potential for radiosensitization of numerous cancers, including glioblastomas, which are extremely radio- and chemoresistant brain tumors, Currently, there are no DNA double-strand break (DSB) repair inhibitors that have been successful in treating glioblastoma. Our laboratory previously demonstrated that the dual phosphoinositide 3-kinase/mTOR inhibitor NVP-BEZ235 can potently inhibit the two central DDR kinases, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ataxia-telangiectasia mutated (ATM), in vitro, Here, we tested whether NVP-BEZ235 could also inhibit ATM and DNA-PKcs in tumors in viva and assessed its potential as a radio- and chemosensitizer in preclinical mouse glioblastoma models. Experimental Design: The radiosensitizing effect of NVP-BEZ235 was tested by following tumor growth in subcutaneous and ortho topic glioblastoma models, Tumors were generated using the radioresistant U87-vIII glioma cell line and GBM9 neurospheres in nude mice. These tumors were then treated with ionizing radiation and/or NVP-BEZ235 and analyzed for DNA-PKcs and ATM activation, DSB repair inhibition, and attenuation of growth. Results: NVP-BEZ235 potently inhibited both DNA-PKcs and ATM kinases and attenuated the repair of ionizing radiation-induced DNA damage in tumors. This resulted in striking tumor radiosensitization, which extended the survival of brain tumor-bearing mice. Notably, tumors displayed a higher DSB-load when compared with normal brain tissue. NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma. Conclusions: These results demonstrate that it may be possible to significantly improve glioblastoma therapy by combining ionizing radiation with potent and bioavailable DNA repair inhibitors such as NVP-BEZ235. (C) 2013 AACR.
引用
收藏
页码:1235 / 1248
页数:14
相关论文